Armistice Capital LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,476,000 shares of the company's stock, valued at approximately $5,874,000. Armistice Capital LLC owned approximately 0.76% of ImmunityBio as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently bought and sold shares of the company. Point72 Hong Kong Ltd boosted its position in ImmunityBio by 2,136.0% during the first quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company's stock worth $34,000 after purchasing an additional 5,874 shares in the last quarter. Toroso Investments LLC purchased a new stake in ImmunityBio during the first quarter worth $63,000. Apollon Wealth Management LLC purchased a new stake in ImmunityBio during the first quarter worth $25,000. Aire Advisors LLC purchased a new stake in ImmunityBio during the third quarter worth $25,000. Finally, FMR LLC boosted its position in ImmunityBio by 190.0% during the third quarter. FMR LLC now owns 14,881 shares of the company's stock worth $25,000 after purchasing an additional 9,749 shares in the last quarter. 8.60% of the stock is currently owned by hedge funds and other institutional investors.
ImmunityBio Stock Down 0.4 %
Shares of NASDAQ:IBRX traded down $0.02 on Friday, hitting $4.71. The company had a trading volume of 3,215,542 shares, compared to its average volume of 4,432,305. ImmunityBio, Inc. has a 52-week low of $1.21 and a 52-week high of $6.93. The business has a 50 day moving average of $4.27 and a 200 day moving average of $3.14.
About ImmunityBio
(
Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.
Featured Stories
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
